The clinical relevance of potential drug-drug interactions (DDIs) with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) – Real-world data from the German IQVIA prescription database

Tim Umland1, Hans-Jürgen Stellbrink2, Marta Calvo3, Astrid Zahn4

1Alexandra Apotheke, Hamburg, Germany; 2Häkelnarkotikum-Behandlungszentrum Hamburg (iCH), Hamburg, Germany; 3Gilead Sciences GmbH, Munich, Germany

Background

As people living with HIV (PLWH) age on antiretroviral treatment (ART), co-medication with no or low interaction potential is becoming more relevant in everyday clinical practice. This analysis of longitudinal prescription information in PLWH in Germany focuses on the frequency of concomitant drugs and potential DDIs with ART in PLWH receiving B/F/TAF.

Methods

Data were obtained using the IMS® LRx database (IQVIA), which covered about 80% of prescriptions reimbursed by German statutory health insurance providers from 07/2018 to 06/2019, i.e. the MAT (moving annual total) as of 06/2019, one year after market authorization of B/F/TAF in Europe.

- The study population consists of PLWH on continuous B/F/TAF for 3 months.
- Co-medications of patients are analyzed on the basis of EpiMRa ATC (European Pharmaceutical Market Research Association Anatomical Therapeutic Chemical) level 3 and substances.
- The HIV Drug Interaction database of the University of Liverpool (https://www.hiv-druginteractions.org/checker) was used to determine the DDIs between prescribed concomitant medications and B/F/TAF. In this database, green color signals “no interaction expected”, amber/orange “potential interaction” and red “contraindication, co-administration not recommended”.

Results

Study population

Among 4,893 PLWH on B/F/TAF, 3,764 PLWH (77%) received ≥1 co-medication.

- Of those, 69% were men, 13% women, 18% of unknown gender. The majority of patients was between 41 and 60 years old (59%) (440 years (29%) and 61 years (12%)).
- The mean (median) number of co-medications was 4.0 (3.0) (Figure 1).

Figure 1. Number of co-medications stratified by age and gender (in PLWH on co-medication)

Interaction potential of concomitant medications

Several of the most commonly used co-medication classes posed no interaction risk to B/F/TAF according to the Liverpool database. Among those were antiulcerants (the most frequently prescribed substance was pantoprazole, 16% of 3,764, n=620), anti- rheumatics (luprofen, 15%, n=565), anti-depressants (mirtazapine, 3%, n=102) and lipid lowering agents (atorvastatin, 7%, n=276). Figure 4 shows the DDI profile of the study cohort; of note, some drug classes used by the Liverpool database differ from EpiMRa ATC 3 classes (e.g. “antibacterials” encompasses several EpiMRa ATC 3 classes). For ≥50% of PLWH receiving B/F/TAF, the concomitant medications posed no or no relevant risk for interaction.

Conclusions

- In comprehensive overview of concomitant medication, 77% of PLWH on B/F/TAF received ≥1 co-medication. Contraindicated medications were used in ≤0.25% of the cohort. Any drug with potential for DDIs was used in <3% of PLWH on B/F/TAF.
- In those cases with potentially relevant DDI, the individual medications can be replaced by other compounds of the same drug class member without potential interaction with B/F/TAF according to the Liverpool HIV Drug Interaction database.
- Although this evaluation was limited by the exclusion of over-the-counter drugs with potential for DDIs (such as mineral supplements or St. John’s wort), the overall potential for DDIs with B/F/TAF is low and manageable in clinical practice.

Acknowledgments

- Design, study conduct and financial support were provided by Gilead Sciences.
- Support in medical writing was provided by MUD, Research, Munich, Germany.

References